Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced the US Food and Drug Administration (FDA...
Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana PR Newswire MELBOURNE, Australia and SAN...
PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model...
Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today...
Highlights: Prana enrols and doses its first cohort of healthy volunteers in its Phase I clinical trial Evidence supports activity...
Highlights: Prana receives ethics committee approval for a clinical trial evaluating first in human dosing of PBT434 Recruitment...
PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture Prana Biotechnology...
Scientific Journal Acta Neuropathologica publishes pre-clinical data Prana Biotechnology Ltd (NASDAQ: PRAN) (ASX: PBT) today announced the...
David Stamler, M.D., has joined Prana Biotechnology (ASX: PBT) (NASDAQ: PRAN) as Chief Medical Officer and Senior Vice President, Clinical...
Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지